A multi-center study on the efficacy of eltrombopag in management of refractory chronic immune thrombocytopenia: A real-life experience

Basit Öğe Kaydı
dc.authorid0000-0003-2090-4392en_US
dc.contributor.authorÇekdemir, Demet
dc.contributor.authorGüvenç, Serkan
dc.contributor.authorÖzdemirkıran, Füsun Gediz
dc.contributor.authorEser, Ali
dc.contributor.authorToptaş, Tayfur
dc.contributor.authorÖzkocaman, Vildan
dc.contributor.authorŞahin, Handan Haydaroǧlu
dc.contributor.authorTurak, Esra Ermiş
dc.contributor.authorEsen, Ramazan
dc.contributor.authorCömert, Melda
dc.contributor.authorSadri, Sevil
dc.contributor.authorAslaner, Müzeyyen
dc.contributor.authorUncu Ulu, Bahar
dc.contributor.authorBapur, Derya Selim
dc.contributor.authorAlacacıoğlu, İnci
dc.contributor.authorAydın, Demet
dc.contributor.authorTekinalp, Atakan
dc.contributor.authorNamdaroǧlu, Sinem
dc.contributor.authorCeran, Funda
dc.contributor.authorTarkun, Pınar
dc.contributor.authorKiper, Demet
dc.contributor.authorÇetiner, Mustafa
dc.contributor.authorYenerel, Mustafa Nuri
dc.contributor.authorDemir, Ahmet Muzaffer
dc.contributor.authorYılmaz, Güven
dc.contributor.authorTerzi, Hatice
dc.contributor.authorAtilla, Erden
dc.contributor.authorMalkan, Ümit Yavuz
dc.contributor.authorAcar, Kadir
dc.contributor.authorÖztürk, Erman
dc.contributor.authorTombak, Anıl
dc.contributor.authorSunu, Cenk
dc.contributor.authorSalim, Ozan
dc.contributor.authorAlayvaz, Nevin
dc.contributor.authorSayan, Özkan
dc.contributor.authorOzan, Ülkü
dc.contributor.authorAyer, Mesut
dc.contributor.authorGökgöz, Zafer
dc.contributor.authorAndıç, Neslihan
dc.contributor.authorKızılkılıç, Ebru
dc.contributor.authorNoyan, Figen
dc.contributor.authorÖzen, Mehmet
dc.contributor.authorTanrıkulu, Funda Pepedil
dc.contributor.authorAlanoǧlu, Gü̧chan
dc.contributor.authorÖzkan, Hasan Atilla
dc.contributor.authorAslan, Vahap
dc.contributor.authorÇetin, Güven
dc.contributor.authorErikçi, Alev Akyol
dc.contributor.authorDeveci, Burak
dc.contributor.authorDursun, Fadime Ersoy
dc.contributor.authorDermenci, Hasan
dc.contributor.authorAytan, Pelin
dc.contributor.authorGündüz, Mehmet
dc.contributor.authorKarakuş, Volkan
dc.contributor.authorÖzlü, Can
dc.contributor.authorDemircioğlu, Sinan
dc.contributor.authorYanar, Olga Meltem Akay
dc.contributor.authorÖzatlı, Düzgün
dc.contributor.authorÜndar, Levent
dc.contributor.authorTiftik, Eyüp Naci
dc.contributor.authorSucak, Ayhan Gülsan Türköz
dc.contributor.authorHaznedaroğlu, İbrahim Celalettin
dc.contributor.authorÖzcan, Muhit
dc.contributor.authorŞencan, Mehmet
dc.contributor.authorTombuloğu, Murat
dc.contributor.authorÖzet, Gülsüm Gulistan
dc.contributor.authorBilgir, Oktay
dc.contributor.authorTurgut, Burhan
dc.contributor.authorÖzcan, Mehmet Ali
dc.contributor.authorPayzın, Kadriye Bahriye
dc.contributor.authorSönmez, Mehmet
dc.contributor.authorAyyıldız, Orhan
dc.contributor.authorDal, Mehmet Sinan
dc.contributor.authorErtop, Şehmus
dc.contributor.authorTurgut, Mehmet
dc.contributor.authorSoysal, Teoman
dc.contributor.authorKaya, Emin
dc.contributor.authorÜnal, Ali Ekrem
dc.contributor.authorPehlivan, Mustafa
dc.contributor.authorAtagündüz, Işık Kaygusuz
dc.contributor.authorFıratlı, Tülin Tuğlular
dc.contributor.authorSaydam, Güray
dc.contributor.authorKüçükkaya, Reyhan Diz
dc.date.accessioned2021-09-28T08:06:09Z
dc.date.available2021-09-28T08:06:09Z
dc.date.issued2019en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıklar Ana Bilim Dalıen_US
dc.descriptionPMID:31327186
dc.description.abstractObjective: The aim of the present study was to evaluate the efficacy and safety of eltrombopag, an oral thrombopoietin receptor agonist, in patients with chronic immune thrombocytopenia (ITP). Materials and Methods: A total of 285 chronic ITP patients (187 women, 65.6%; 98 men, 34.4%) followed in 55 centers were enrolled in this retrospective cohort. Response to treatment was assessed according to platelet count (/mm3) and defined as complete (platelet count of >100,000/mm3), partial (30,000-100,000/mm3 or doubling of platelet count after treatment), or unresponsive (<30,000/mm3). Clinical findings, descriptive features, response to treatment, and side effects were recorded. Correlations between descriptive, clinical, and hematological parameters were analyzed. Results: The median age at diagnosis was 43.9±20.6 (range: 3-95) years and the duration of follow-up was 18.0±6.4 (range: 6-28.2) months. Overall response rate was 86.7% (n=247). Complete and partial responses were observed in 182 (63.8%) and 65 (22.8%) patients, respectively. Thirty-eight patients (13.4%) did not respond to eltrombopag treatment. For patients above 60 years old (n=68), overall response rate was 89.7% (n=61), and for those above 80 years old (n=12), overall response rate was 83% (n=10). Considering thrombocyte count before treatment, eltrombopag significantly increased platelet count at the 1st, 2nd, 3rd, 4th, and 8th weeks of treatment. As the time required for partial or complete response increased, response to treatment was significantly reduced. The time to reach the maximum platelet levels after treatment was quite variable (1-202 weeks). Notably, the higher the maximum platelet count after eltrombopag treatment, the more likely that side effects would occur. The most common side effects were headache (21.6%), weakness (13.7%), hepatotoxicity (11.8%), and thrombosis (5.9%). Conclusion: Results of the current study imply that eltrombopag is an effective therapeutic option even in elderly patients with chronic ITP. However, patients must be closely monitored for response and side effects during treatment. Since both response and side effects may be variable throughout the follow-up period, patients should be evaluated dynamically, especially in terms of thrombotic risk factors.en_US
dc.identifier.citationÇekdemir, D., Güvenç, S., Özdemirkıran, F. G., Eser, A., Toptaş, T., Özkocaman, V. ve diğerleri (2019). A multi-center study on the efficacy of eltrombopag in management of refractory chronic immune thrombocytopenia: A real-life experience. Turkish Journal of Hematology, 36(4), 230-237.en_US
dc.identifier.doi10.4274/tjh.galenos.2019.2018.0307en_US
dc.identifier.endpage237en_US
dc.identifier.issn1300-7777
dc.identifier.issue4en_US
dc.identifier.pmid31327186en_US
dc.identifier.scopus2-s2.0-85075099354en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage230en_US
dc.identifier.trdizinidhttps://search.trdizin.gov.tr/yayin/detay/353770en_US
dc.identifier.urihttps://jag.journalagent.com/tjh/pdfs/TJH_36_4_230_237.pdf
dc.identifier.urihttps://hdl.handle.net/11468/7806
dc.identifier.volume36en_US
dc.identifier.wosWOS:000497303100003
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.indekslendigikaynakTR-Dizin
dc.institutionauthorKarakuş, Abdullah
dc.language.isoenen_US
dc.publisherTurkish Society of Hematologyen_US
dc.relation.ispartofTurkish Journal of Hematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectEltrombopagen_US
dc.subjectImmune thrombocytopenicen_US
dc.subjectThrombocytopeniaen_US
dc.titleA multi-center study on the efficacy of eltrombopag in management of refractory chronic immune thrombocytopenia: A real-life experienceen_US
dc.title.alternativeRefrakter kronik immün trombositopeni tedavisinde eltrombopagın etkinliğine ilişkin çok merkezli bir çalışma: Gerçek yaşam deneyimien_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
A Multi-Center Study on the Efficacy of Eltrombopag in.pdf
Boyut:
270.74 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu